Lessons learned from development of docetaxel (Q58382477)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624687%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

review article

1 reference

title

Lessons learned from development of docetaxel (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624687%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624687%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

Christopher Sweeney

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624687%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

language of work or name

English

0 references

publication date

1 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624687%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Metabolism & Toxicology

10 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624687%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624687%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

1007-1019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624687%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624687%20AND%20SRC:MED&resulttype=core&format=json

Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines

10 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

In vitro cytotoxic activity of Taxol and Taxotere on primary cultures and established cell lines of human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Phase I trial of Taxotere: five-day schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Docetaxel administration schedule: from fever to tears? A review of randomised studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

A rapid and sensitive liquid chromatography/tandem mass spectrometry method for determination of docetaxel in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Determination of unbound docetaxel and paclitaxel in plasma by ultrafiltration and liquid chromatography-tandem mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Limited cerebrospinal fluid penetration of docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Relationship of systemic exposure to unbound docetaxel and neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Role of formulation vehicles in taxane pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Clinical pharmacokinetics of docetaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Evaluation of the linearity of docetaxel pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Pharmacokinetics and toxicity of weekly docetaxel in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Clinical pharmacodynamic factors in docetaxel toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Genome-wide discovery of loci influencing chemotherapy cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Drug interactions with the taxanes: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Influence of ketoconazole on the fecal and urinary disposition of docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.7.1007

10.1517/17425255.4.7.1007

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18624687%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference